Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-228
Authors: Russo, Alexandra
Paret, Claudia
Alt, Francesca
Burhenne, Jürgen
Fresnais, Margaux
Wagner, Wolfgang
Glaser, Martin
Bender, Hannah
Huprich, Sabrina
Harter, Patrick N.
Filipski, Katharina
Lehmann, Nadine
Backes, Nora
Roth, Lea
Seidmann, Larissa
Sommer, Clemens
Brockmann, Marc
Pietsch, Torsten
Neu, A. Marie
Wingerter, Arthur
Faber, Jörg
Title: Ceritinib-induced regression of an insulin-like growth factor-driven neuroepithelial brain tumor
Online publication date: 11-Nov-2019
Language: english
Abstract: The insulin-like growth factor (IGF) pathway plays an important role in several brain tumor entities. However, the lack of inhibitors crossing the blood–brain barrier remains a significant obstacle for clinical translation. Here, we targeted the IGF pathway using ceritinib, an off-target inhibitor of the IGF1 receptor (IGF1R) and insulin receptor (INSR), in a pediatric patient with an unclassified brain tumor and a notch receptor 1 (NOTCH1) germline mutation. Pathway analysis of the tumor revealed activation of the sonic hedgehog (SHH), the wingless and integrated-1 (WNT), the IGF, and the Notch pathway. The proliferation of the patient tumor cells (225ZL) was inhibited by arsenic trioxide (ATO), which is an inhibitor of the SHH pathway, by linsitinib, which is an inhibitor of IGF1R and INSR, and by ceritinib. 225ZL expressed INSR but not IGF1R at the protein level, and ceritinib blocked the phosphorylation of INSR. Our first personalized treatment included ATO, but because of side effects, we switched to ceritinib. After 46 days, we achieved a concentration of 1.70 µM of ceritinib in the plasma, and after 58 days, MRI confirmed that there was a response to the treatment. Ceritinib accumulated in the tumor at a concentration of 2.72 µM. Our data suggest ceritinib as a promising drug for the treatment of IGF-driven brain tumors.
DDC: 610 Medizin
610 Medical sciences
Institution: Johannes Gutenberg-Universität Mainz
Department: FB 04 Medizin
Place: Mainz
DOI: http://doi.org/10.25358/openscience-228
URN: urn:nbn:de:hebis:77-publ-594122
Version: Published version
Publication type: Zeitschriftenaufsatz
License: CC BY
Information on rights of use: https://creativecommons.org/licenses/by/4.0/
Journal: International journal of molecular sciences
20
17
Pages or article number: Art. 4267
Publisher: Molecular Diversity Preservation International
Publisher place: Basel
Issue date: 2019
ISSN: 1422-0067
1661-6596
Publisher URL: http://dx.doi.org/10.3390/ijms20174267
Publisher DOI: 10.3390/ijms20174267
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
59412.pdf4.35 MBAdobe PDFView/Open